Literature DB >> 31187175

Radiation-induced glucocorticoid receptor promotes CD44+ prostate cancer stem cell growth through activation of SGK1-Wnt/β-catenin signaling.

Feng Chen1,2, Xiaodong Chen1,2, Yu Ren2, Guobin Weng2, Peter C Keng1, Yuhchyau Chen3,4, Soo Ok Lee5,6.   

Abstract

We observed cancer stem cell (CSC) population increase in radioresistant LNCaP (LNCaPR18) and C4-2 (C4-2R26) prostate cancer (PCa) cells compared with respective parental cells. Since the CD44 level increase was most significant in radioresistant PCa cells compared with parental cells among CSC markers tested, we isolated the CD44+ population from LNCaP/LNCaPR18 and C4-2/C4-2R26 cell sets via the immunomagnetic separation method and used them as CSC sources. We detected lower AR level, but higher glucocorticoid receptor (GR) level in CD44+ CSCs than CD44- non-CSCs. Higher GR level in CD44+ CSCs than CD44- cells was also detected when cells were isolated from mouse tumor tissues of LNCaPR18 cell and C4-2R26 cell-derived human xenografts and grown in culture. We then found blocking the GR signaling by adding the anti-GR agent mifepristone into the cell culture inhibited the CD44+ CSC growth while the addition of the anti-AR agent enzalutamide enhanced the CSC growth. In xenograft mouse studies in which tumors were developed from the injection of CD44+ CSCs of LNCaPR18 or C4-2R26 cell lines, retarded tumor growth in mifepristone-injected mice was observed compared with vehicle-treated mice. We next discovered the GR regulation of Wnt/β-catenin signaling pathway. We further found that the serum/glucocorticoid regulated kinase 1 (SGK1) is the GR downstream molecule that mediates Wnt/β-catenin signaling activation. Therefore, inhibition of either SGK1 or Wnt/β-catenin signaling impaired the in vitro CD44+ CSC growth. From these results, we suggest that blocking GR signaling or its downstream SGK1-Wnt/β-catenin signaling axis may suppress the radiation-induced CSC increase in PCa. KEY MESSAGES: Higher CSC population exists in radioresistant PCa cells than parental cells. Higher GR levels (and lower AR level) in CD44+ CSCs than CD44- non-CSCs. Use of anti-GR agent blocked the growth of CD44+ CSCs in in vitro/in vivo tests. GR downstream SGK1-Wnt/β-catenin signaling axis mediates the CSC increase. Targeting this signaling axis may enhance the radiotherapy efficacy in treating PCa.

Entities:  

Keywords:  GR; Prostate cancer stem cells; Radioresistance; SGK1; Wnt/β-catenin

Mesh:

Substances:

Year:  2019        PMID: 31187175     DOI: 10.1007/s00109-019-01807-8

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  41 in total

1.  Racial treatment trends in localized/regional prostate carcinoma: 1992-1999.

Authors:  Willie Underwood; James Jackson; John T Wei; Rodney Dunn; Edmond Baker; Sonya Demonner; David P Wood
Journal:  Cancer       Date:  2005-02-01       Impact factor: 6.860

2.  Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells.

Authors:  L Patrawala; T Calhoun; R Schneider-Broussard; H Li; B Bhatia; S Tang; J G Reilly; D Chandra; J Zhou; K Claypool; L Coghlan; D G Tang
Journal:  Oncogene       Date:  2006-03-16       Impact factor: 9.867

Review 3.  Androgen receptor in prostate cancer.

Authors:  Cynthia A Heinlein; Chawnshang Chang
Journal:  Endocr Rev       Date:  2004-04       Impact factor: 19.871

Review 4.  Androgen receptor: an overview.

Authors:  C Chang; A Saltzman; S Yeh; W Young; E Keller; H J Lee; C Wang; A Mizokami
Journal:  Crit Rev Eukaryot Gene Expr       Date:  1995       Impact factor: 1.807

Review 5.  Exploring the role of cancer stem cells in radioresistance.

Authors:  Michael Baumann; Mechthild Krause; Richard Hill
Journal:  Nat Rev Cancer       Date:  2008-05-30       Impact factor: 60.716

6.  Factors implicated in radiation therapy failure and radiosensitization of prostate cancer.

Authors:  Helmut Bonkhoff
Journal:  Prostate Cancer       Date:  2011-09-08

7.  Radiation induces the generation of cancer stem cells: A novel mechanism for cancer radioresistance.

Authors:  Fengsheng Li; Kunming Zhou; Ling Gao; Bin Zhang; Wei Li; Weijuan Yan; Xiujun Song; Huijie Yu; Sinian Wang; Nan Yu; Qisheng Jiang
Journal:  Oncol Lett       Date:  2016-09-12       Impact factor: 2.967

Review 8.  Prostate Cancer Radiation Therapy: What Do Clinicians Have to Know?

Authors:  Ben G L Vanneste; Evert J Van Limbergen; Emile N van Lin; Joep G H van Roermund; Philippe Lambin
Journal:  Biomed Res Int       Date:  2016-12-28       Impact factor: 3.411

9.  ELF5-Mediated AR Activation Regulates Prostate Cancer Progression.

Authors:  Kai Li; Yongmin Guo; Xiong Yang; Zhihong Zhang; Changwen Zhang; Yong Xu
Journal:  Sci Rep       Date:  2017-03-13       Impact factor: 4.379

10.  Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes.

Authors:  Roberto Gomez-Casal; Chitralekha Bhattacharya; Nandita Ganesh; Lisa Bailey; Per Basse; Michael Gibson; Michael Epperly; Vera Levina
Journal:  Mol Cancer       Date:  2013-08-16       Impact factor: 27.401

View more
  5 in total

Review 1.  The prospect of serum and glucocorticoid-inducible kinase 1 (SGK1) in cancer therapy: a rising star.

Authors:  Ruizhe Zhu; Gang Yang; Zhe Cao; Kexin Shen; Lianfang Zheng; Jianchun Xiao; Lei You; Taiping Zhang
Journal:  Ther Adv Med Oncol       Date:  2020-07-15       Impact factor: 8.168

2.  Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.

Authors:  Federica Iannelli; Maria Serena Roca; Rita Lombardi; Chiara Ciardiello; Laura Grumetti; Simona De Rienzo; Tania Moccia; Carlo Vitagliano; Angela Sorice; Susan Costantini; Maria Rita Milone; Biagio Pucci; Alessandra Leone; Elena Di Gennaro; Rita Mancini; Gennaro Ciliberto; Francesca Bruzzese; Alfredo Budillon
Journal:  J Exp Clin Cancer Res       Date:  2020-10-08

3.  The Antiasthma Medication Ciclesonide Suppresses Breast Cancer Stem Cells through Inhibition of the Glucocorticoid Receptor Signaling-Dependent YAP Pathway.

Authors:  Su-Lim Kim; Hack Sun Choi; Ji-Hyang Kim; Dong-Sun Lee
Journal:  Molecules       Date:  2020-12-19       Impact factor: 4.411

Review 4.  Cancer Stem Cell Markers for Urinary Carcinoma.

Authors:  Pu Xia; Da-Hua Liu; Ze-Jun Xu; Fu Ren
Journal:  Stem Cells Int       Date:  2022-03-15       Impact factor: 5.443

5.  Multiomics Differences in Lung Squamous Cell Carcinoma Patients with High Radiosensitivity Index Compared with Those with Low Radiosensitivity Index.

Authors:  Yajing Du; Sujuan Yuan; Xibing Zhuang; Qi Zhang; Tiankui Qiao
Journal:  Dis Markers       Date:  2021-08-30       Impact factor: 3.434

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.